AbbVie Inc (ABBV)vsAveanna Healthcare Holdings Inc (AVAH)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
AVAH
Aveanna Healthcare Holdings Inc
$6.55
-2.24%
HEALTHCARE · Cap: $1.42B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2414% more annual revenue ($61.16B vs $2.43B). AVAH leads profitability with a 9.3% profit margin vs 6.9%. AVAH trades at a lower P/E of 6.2x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AVAH
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+57.0%
Fair Value
$18.54
Current Price
$6.55
$11.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 62 in profit
Earnings expanding 465.2% YoY
Revenue surging 27.4% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : AVAH
The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 27.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : AVAH
The primary concerns for AVAH are Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while AVAH is a growth play — different risk/reward profiles.
AVAH carries more volatility with a beta of 2.09 — expect wider price swings.
AVAH is growing revenue faster at 27.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 62/100). AVAH offers better value entry with a 57.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Aveanna Healthcare Holdings Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?